Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dual inhibition of angiopoietin-TIE2 and MET alters the tumor microenvironment and prolongs survival in a metastatic model of renal cell carcinoma.
|
31582532 |
2020 |
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cabozantinib is a potent inhibitor of VEGF, AXL and MET receptors providing rationale for its use in RCC.
|
31184937 |
2019 |
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Other tyrosine kinases' pathways, including PDGFR, Axl or MET have emerged as key signaling pathways involved in RCC biology.
|
30999623 |
2019 |
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combination strategies of VEGF and MET inhibitors could lead to sustained and deep responses even in non-MET driven RCC by inhibiting pathways of VEGF resistance.
|
31554440 |
2019 |
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Likewise, papillary RCC has also been studied at the molecular level, which has shown a high level of mutations in the MET gene; early clinical data suggest the utility of MET targeted therapy.
|
30478013 |
2018 |
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The significance of ligand-dependent MET activation in RCC bone metastasis is considered, and HAI-2 may be an important regulator in this system.
|
29890660 |
2018 |
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Fishing wild-type sparing inhibitors of proto-oncogene c-met variants in renal cell carcinoma from a curated tyrosine kinase inhibitor pool using analog-sensitive kinase technology.
|
30017898 |
2018 |
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET inhibitors are actively being developed for papillary RCC with a specific focus on MET-driven tumors.
|
30372389 |
2018 |
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mechanistic, preclinical, and early clinical data highlight c-Met / hepatocyte growth factor receptor as a promising target for RCC therapeutic agents.We have examined MET expression, frequency of MET gene copy gains and MET gene mutation in a large, hospital-based series of renal cell carcinomas with long-term follow-up information.Out of a total of 572 clear-cell RCC, only 17% were negative for MET expression whereas 32% showed high protein levels.
|
27894094 |
2017 |
Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
C-Met protein levels were increased in 8 of 10 RCC tissue samples compared with their adjacent normal tissue and c-Met expression levels were positively associated with a high nuclear grade (P = 0.008) and pT stage (P = 0.002).
|
28427859 |
2017 |
Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We report here two pediatric patients with recurrent metastatic RCC whose tumors expressed MET and were treated with cabozantinib.
|
28417541 |
2017 |
Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interfering RNA-induced stable inhibition of <i>NRF2</i> in ovarian carcinoma SKOV3 and renal carcinoma A498 reduced the levels of c-MET and EGFR.
|
29291022 |
2017 |
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, tissue microarrays containing sunitinib-treated and untreated RCC tissues were stained with MET and AXL antibodies.
|
26364599 |
2016 |
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Renal cell carcinoma (RCC) is a metabolic disease, being characterized by the dysregulation of metabolic pathways involved in oxygen sensing (VHL/HIF pathway alterations and the subsequent up-regulation of HIF-responsive genes such as VEGF, PDGF, EGF, and glucose transporters GLUT1 and GLUT4, which justify the RCC reliance on aerobic glycolysis), energy sensing (fumarate hydratase-deficient, succinate dehydrogenase-deficient RCC, mutations of HGF/MET pathway resulting in the metabolic Warburg shift marked by RCC increased dependence on aerobic glycolysis and the pentose phosphate shunt, augmented lipogenesis, and reduced AMPK and Krebs cycle activity) and/or nutrient sensing cascade (deregulation of AMPK-TSC1/2-mTOR and PI3K-Akt-mTOR pathways).
|
27453294 |
2016 |
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CTC FISH demonstrated that MET amplification in both gastric and colorectal cancer patients and trisomy 7 with gain of MET gene copies in the RCC patient.
|
26951228 |
2016 |
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.
|
25401301 |
2015 |
Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.
|
25186085 |
2015 |
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Dysregulation of c-Met and hepatocyte growth factor have been observed in both clear cell and non-clear cell renal cell carcinomas (RCCs), although only papillary RCCs harbor activating mutations in the MET gene.
|
23867513 |
2014 |
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
If these results are further validated in a similar population, they could be incorporated into future prognostic instruments, potentially aiding the design of adjuvant clinical trials of MET inhibitors and management of renal-cell carcinoma.
|
24767687 |
2014 |
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
|
24658158 |
2014 |
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
If these results are further validated in a similar population, they could be incorporated into future prognostic instruments, potentially aiding the design of adjuvant clinical trials of MET inhibitors and management of renal-cell carcinoma.
|
23219378 |
2013 |
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Investigation of rare familial forms of renal cell carcinoma (RCC) has led to the identification of genes such as VHL and MET that are also implicated in the pathogenesis of sporadic RCC.
|
24000165 |
2013 |
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Common genetic aberrations in renal cell carcinomas (RCCs) include loss of function of the VHL gene in clear-cell RCC, overexpression of the c-MET gene in papillary RCC type I, deficiency in the FH gene in papillary RCC type II and loss of heterozygozity of the BHD gene in chromophobe RCC.
|
23895657 |
2013 |
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in the MET and fumarate hydratase (FH) genes lead to the development of type 1 and type 2 papillary RCCs, respectively, and such mutations of either the TSC1 or TSC2 gene increase the risk of RCC.
|
21228928 |
2010 |
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MET is the gene for the hereditary form of type 1 papillary renal carcinoma and is mutated in a subset of sporadic type 1 papillary kidney cancers.
|
20059341 |
2010 |